Tetraphase Pharmaceuticals

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) infections. Since the company’s inception in 2006, Tetraphase has developed an antibiotics platform that offers the potential to dramatically improve the treatment of both broad-spectrum and MDR bacterial infections.

NASDAQ: TTPH

Pipeline   Partnerships


Our lead product candidate, eravacycline, is being developed as a broad-spectrum IV and oral antibiotic in our Phase 3 IGNITE program for the indications of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). Read more about the company’s advancing clinical pipeline. More >>


With its innovative antibiotics platform, Tetraphase offers significant value for leading pharmaceutical companies. If you are interested in partnering with Tetraphase... More >>


News

More >>




      Legal Notes / Privacy © 2014 Tetraphase Pharmaceuticals